MediciNova, Inc. 2012 Forward Looking Statements Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Sec

Pail Rolan at Univ. of Adelaide, Australia; reduced headache index, acute medication (codeine) use and headache impact on Quality of Life (QOL); 8 week trial + follow up; n = 20 patients each at placebo vs. 80 mg/day of MN 166 Acquired rights to treatment of post traumatic brain injury (TBI) Led by the research of Daniel Barth, Ph.D., Professor of Neuroscience and Psychology at CU Boulder, ibudilast demonstrated significant efficacy in a model of post TBI anxiety, one of the most common disorders caused by TBI.

Potential first in class, once or twice daily oral well tolerated drug with established endpoints. Draft protocols, costs and trial operations completed. MediciNova, Inc. 2012 Recent validation of CNS action in opioid withdrawal analgesia Ongoing Methamphetamine interaction Phase 1b Opioid self administration Phase 2a initiating Ongoing Phase 2a Medication Overuse Headache Pain trial Randomized, double blind, placebo controlled, investigator initiated (Dr.

Potential first in class, once or twice daily oral well tolerated drugs with established endpoints. Draft protocols, costs, and trial operations completed. MediciNova, Inc. 2012 43 Diabetic Peripheral Neuropathic Pain Study: AV411 010 Design: Two center (Australian), Phase 1b/2a, randomized, double blind, placebo controlled, parallel group study. Subjects: Patients, aged 18 to 75 years, with painful diabetic peripheral neuropathy (DPN) or complex regional pain syndrome (CRPS) of 6 months duration and screening VAS score 4 cm on a 10 cm scale 29 subjects: 19 active, 10 placebo Dosing: 20 mg BID (n=4), 20 mg TID (n=4), 40 mg BID (n=11) AV411 added to patients standard medication regimen for DM and pain Study objectives: Establish safety/tolerability PK in intended patient population Explore potential efficacy endpoints MediciNova, Inc. 2012 Reduction Observed in Opioid Usage 44 MediciNova, Inc. 2012 45 Greater % of Responders Above Ibudilast Plasma Thresholds Plasma Ibudilast Parameter VAS Responder % AUC 0 24h 1000 nghr/mL 60% 1000 nghr/mL 25% C max 60 ng/mL 64% 60 ng/mL 14% C min 27 ng/mL 55% 27 ng/mL 29% Next Steps for Neuropathic Pain: Twelve week Phase 2 DPN trial.

Safety Profile: 89% (264 of 297) of subjects completed the first 12 months of the study 82.5% (245 of 297) of subjects completed the full 24 months of the study Adverse effects reported more frequently in MN 166 treated than placebo treated subjects: GI effects depression Multiple Sclerosis Clinical Study: Multiple Sclerosis Clinical Study: MN 166 CL 001 MN 166 CL 001 39 40 P Value: 0.0 4 P Value: 0.035 MN 166 CL 001 Study Results P Value: 0.02 6 P Value: 0.00 4 P Value: 0.0 9 P Value: 0.0 8 Note: P values listed on this slide compare placebo group to 60mg/day group of MN 166 Indicative of Potential Neuroprotective Effect: Reduced brain volume loss Reduced conversion of acute lesions to persistent black holes Sustained disability progression was significantly less likely (~50%) Acute Clinical Benefit: Prolong time to relapse (by 127 days.) Annualized relapse rate Protocol Defined Primary Endpoint (Surrogate Endpoint): No significant reduction in the cumulative number of active (gadolinium enhancing (T1) and non enhancing new/enlarging (T2)) lesions on cranial MRI scans over 12 months of treatment was observed Positive trends were observed in volume of gadolinium enhancing (T1) lesions MediciNova, Inc. 2012 41 MN 166 CL 001: Efficacy Review (One Year) Endpoints Indicative of Disease Modifying Effect (Chronic aspects of MS): Endpoints Relating to Acute Clinical Benefit: Brain Volume Loss Progression to PBH EDSS progression 0 0.4 0.8 1.2 1.6 2 0 20 40 60 80 100 Dose (mg/d) 0 0.1 0.2 0.3 0.4 0 20 40 60 80 100 Dose (mg/d) 0 2 4 6 8 10 0 20 40 60 80 100 Dose (mg/d) 0 20 40 60 80 100 Dose (mg/d) Time to 1st Relapse 20 30 40 50 60 70 80 90 0 20 40 60 80 100 Dose (mg/d) % Relapse Free After One Year : Statistically significant 0 100 200 300 400 500 600 700 MediciNova, Inc. 2012 MediciNova, Inc. 2012 42 Secondary Progressive MS Subset Analysis Treatment Group (patient n) Subset of MS Patients: Placebo 30 mg/day Low Dose Group 60 mg/day High Dose Group % Brain Volume Change % Brain Volume Change Magnitude of Effect % Brain Volume Change Magnitude of Effect RRMS 1.2 (81) 1.1 (69) 8% less 0.8 (75) 33% less SPMS 1.0 (3) 0.7 (4) 30% less 0.4 (2) 60% less Next Steps for Progressive MS: Two year Phase 2 in Progressive MS month 12 data.

MN 221 (bedoradrine) Administered with Nebulized Albuterol in Dogs (Poster #147) Pharmacokinetics and Pharmacodynamics of MN 221 , a Novel Highly Selective Beta2 Adrenergic Agonist for Treatment of Acute Chronic Obstructive Pulmonary Disease (Poster #685) MN 221 CL 010: Intravenous MN 221, a Novel, Highly Selective Beta2 Adrenergic Receptor Agonist, Improves Lung Function in Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients (Poster #686) Posters available on MediciNova website at www.medicinova.com MN 221: CHEST Posters (Nov. 2010) 37 Ibudilast (MN 166/AV411): Data from Completed Trials Multiple Sclerosis Program Neuropathic Pain Program Drug Abuse/Addiction Program Safety Review MediciNova, Inc. 2012 Placebo controlled, Randomized, Double blind Phase II Study: Year 1 Placebo, 30 mg/day, 60mg/day Year 2 30 mg/day, 60mg/day 297 patients (~100 patients/group) 25 sites in Serbia, Ukraine, Belarus, Bulgaria and Romania Key Inclusion Criteria: Males or females aged 18 to 55 years, with relapsing remitting (RR) and/or secondary progressive (SP) Multiple Sclerosis with continued relapses; One MRI scan taken two weeks prior to treatment start using a standardized MRI protocol with at least one Gd enhancing lesion; An Expanded Disability Status Scale (EDSS) score of 5.5 or less at the screening and baseline visits.

MN 221 CL 006 MediciNova, Inc. 2012 MediciNova, Inc. 2012 36 Human Adrenergic Receptor Selectivity Test Drug 1 IC 50 (M) 2 IC 50 (M) 2 Adrenoceptor Selectivity (IC 50 for 1 / IC 50 for 2 ) Levalbuterol 7.40E 06 1.40E 06 5.3 Albuterol 9.40E 06 1.60E 06 5.9 Terbutaline 6.00E 05 6.50E 06 9.2 MN 221 5.90E 06 1.40E 07 42.4 MediciNova, Inc. 2012 MN 221 CL 004: Evaluation of MN 221 (bedoradrine), a Novel, Highly Selective Beta2 Adrenergic Receptor Agonist in Mild to Moderate Asthma via Intravenous Infusion (Poster #145) MN 221 CL 005: Comparison of Administration Rates of MN 221 (bedoradrine), a Novel, Highly Selective Beta2 Receptor Agonist in Patients with Stable Moderate to Severe Asthma (Poster #143) MN 221 CL 006: Reduced Hospital Admission and Improved Pulmonary Function Following Intravenous MN 221 (bedoradrine), a Novel Highly Selective Beta2 Adrenergic Receptor Agonist, Adjunctive to Standard of Care in Severe Acute Exacerbation of Asthma (Poster #144) Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling and Simulation Support the Novelty of MN 221, a Highly Selective Beta2 Adrenergic Agonist for Treatment of Acute Asthma (Poster #146) MN 221 FY08 065: Cardiovascular Effects of i.v.

The main reason they are not used more often is due to safety concerns, particularly cardiovascular side effects. MN 221 Safety Review 34 MediciNova, Inc. 2012 Safety Data: MN 221 CL 006 Mean Heart Rate Change from Baseline 35 * All patients received Standard of Care including inhaled albuter ol, inhaled ipratropium, and steroids. Note: Baseline heart rate: 90 bpm for placebo, 95 bpm for 240 g, 103 bpm for 450 g, and 119 bpm for 1000 1080 g Source: Draft Clinical Study Report No.

In summary, we have not seen clinically significant safety concerns with MN 221 and it has been tested in ~300 subject to date. In the ongoing CL 007 trial our Data Safety Monitoring Board has reviewed safety data for 148 patients with no concerns for continued enrollment. According to interviews of emergency room physicians, less selective injectable beta agonists such as epinephrine and terbutaline are not commonly used to treat acute asthma.

SOC + placebo Hospitalization Rate: MN 221 (all dose groups) + SOC vs. SOC + placebo CL 006: Patients Suffering from Acute Exacerbation of Asthma in Emergency Department 33 MN 221 Clinical Results Improved Lung Function at Different Dosing Levels: COPD Patients CL 010: Stable Moderate/Severe COPD Patients MediciNova has preclinical data and clinical data which demonstrates the safety of MN 221.

Top Line Results from CL 007 Trial 2. Top Line Results from CL 012 Trial 3. Announce Plan for Ibudilast Raised ~$18M in 2011 Cash Runway into 2013 Clinical development expertise Strong international presence, especially Japan Large and small pharma/biotech experience Addendum Data from Completed Trials MN 221 Ibudilast (MN 166/AV411) MN 221: Data from Completed Trials Asthma Program: CL 004, CL 005, CL 006 COPD Program: CL 010 Safety Review MN 221 Clinical Results Improved Lung Function at Different Dosing Levels: Stable Asthmatics 31 CL 004: Stable Mild/Moderate Asthmatics CL 005: Stable Moderate/Severe Asthmatics MN 221 Clinical Results Improved Lung Function and Clinical Outcome Above and Beyond Standard of Care (SOC) Mean change in FEV 1 from baseline was 5.3% higher in the MN 221 dose groups versus the placebo group MN 221 reduced the hospitalization rate by 45% 32 SOC + placebo SOC + placebo 14.0% 8.7% 46% 25% MN 221 + SOC MN 221 + SOC 0% 2% 4% 6% 8% 10% 12% 14% 16% 0% 10% 20% 30% 40% 50% Mean FEV 1 Change from Baseline (Hour 5) MN 221 (all dose groups) + SOC vs.

Michael Gennaro, CPA, MBA Michael Gennaro, CPA, MBA Chief Financial Officer 37 Partner at FLG Partners, Sylantro Systems, Inverse Network Technology, Novell, Piiceon, Verticom Management Team with Global Experience MediciNova, Inc. 2012 27 Financial Overview ~18.3 million shares outstanding of common + preferred on an as converted basis Cash Runway into 2013 $2.5 million additional payment from Kissei $7.5 million raised in private stock sale to Kissei Pharmaceutical Co., Ltd. $8.7 million in cash cash equivalents as of 9/30/2011 Financial Resources: Kissei purchased 800,000 shares common stock at $2.50/share Kissei purchased 220,000 shares Series B preferred stock at $25.00/share (convertible to common at 1:10 ratio) MediciNova to expand MN 221 program in asthma and COPD +$10 million raised through equity sale and non dilutive funding by Kissei in 4Q, 2011 MediciNova, Inc. 2012 28 MediciNova Corporate Summary *Anticipated completion dates based on current projections 1.

Kirk Johnson, Ph.D. Chief Scientific Officer 21 Avigen, Genesoft Pharmaceuticals, Chiron Corporation (Novartis San Francisco) Masatsune Okajima, CMA Masatsune Okajima, CMA VP, Head of Japanese Office 19 Daiwa Securities SMBC, Sumitomo Capital Securities, Sumitomo Bank Kazuko Matsuda, M.D., Ph.D., MPH Kazuko Matsuda, M.D., Ph.D., MPH Chief Medical Officer 20 Assistant Professor USC, Keck School of Medicine; Children s Hospital Los Angeles.

Could be collaboration through: i. Pharma partner ii. Project financing iii. Shared risk with competitive CRO agreement Sustain NIDA sponsored Drug Addiction Development Potential for Gov t and MS Society consortium funding of Phase 2 POC Trial Consider Investigator sponsored Neurological Trials 24 Strategy for Ibudilast s Development MediciNova, Inc. 2012 25 Patent/Commercial Overview Method of Use MS Neuropathic Pain Composition of Matter AV1013 AV1013 Enantiomer Key: Exp. 2018 Exp. 2025 Exp. 2027 MIF Inh. screen Exp. 2027 Acute Sub chronic Pain Addiction Exp. 2026 Progressive MS Exp. 2029 Issued or Allowed Exp. 2027 Exp. 2028 Pending MOH Pain Anxiety Traumatic Brain Injury/PTSD Ibudilast + Immunomodulator for MS 2 nd Generation Analogs MediciNova, Inc. 2012 26 Leadership Years Experience Background Yuichi Iwaki, MD, PhD Yuichi Iwaki, MD, PhD CEO President 35 Professor at USC, formerly Professor at University of Pittsburgh; Advisor to JAFCO, Tanabe Michael Coffee Michael Coffee Chief Business Officer 26 Avigen, Amarin Corp., Elan Pharmaceuticals, N.A., Athena Neurosciences Kirk Johnson, Ph.D.

Adelaide Phase 2a Trial Methamphetamine Addiction UCLA Phase 1b Trial Ibudilast Ongoing and Future Development 23 *Pending Grant / Partner Funding *Pending Grant / Partner Funding MediciNova, Inc. 2012 Collaboration with Development Partner: 1. Advance to Phase 2b Proof of Concept in MS and/or Pain 2. Provide competitive economics for first in class therapy 3.

(We anticipate this along with pediatric exclusivity and ANDA review time will give us at least 7.0 years of exclusivity) Exclusivity in Europe is 10 years for first approval of new chemical entities In addition, MediciNova has filed multiple patent applications related to MN 221 which if granted, could protect MN 221 until at least 2030 20 Ibudilast (MN 166/AV 411): Progressive Multiple Sclerosis Neuropathic Pain Addiction MediciNova, Inc. 2012 22 Ibudilast Oral administration Safe and well tolerated Approved in Japan/Korea over 3.2M patient exposures 420 subjects treated with ibudilast Dosing up to 100 mg single dose Mechanism(s) of action primarily: Inhibition of macrophage Migration Inhibitor Factor (MIF) PDE 4,10 inhibition Attenuation of glial cell activation Clinical Safety Preliminary Efficacy Established Phase 2 multiple sclerosis proof of concept study Efficacy on disease progression endpoints validated at 60 mg/d Phase 1 dosing to 100 mg/d Phase 1b/2a trial in diabetic neuropathic pain Phase 1b/2a clinical trial in opioid withdrawal analgesia Ibudilast Overview MediciNova, Inc. 2012 1Q 2012 2Q 2012 3Q 2012 4Q 2012 Ibudilast (MN 166/AV11) Program Ibudilast (MN 166/AV11) Program Progressive MS* / Neuropathic Pain* Phase 2b Trial (POC) Opioid Dependence Columbia University Phase 2a Trial Medication Overuse Headache Pain Univ.

S. Hemisphere COPD Program: Multiple doses tested at 1 hour infusion Completed 1 trial in COPD patients with stable disease CL 010 Initiating screening in multi dose trial in patients with stable COPD CL 012 Efficacy and Safety data will also be very useful in further development of MN 221 for acute asthma 15 (23 patients) (17 patients) (29 patients) (~170 200 pts.) (48 patients) (20 patients) MediciNova, Inc. 2012 MN 221 Potential Development 2012 2013 2014 2015 2011 Other Indications? 2016 MN 221: Market Opportunity and Patent Summary MediciNova, Inc. 2012 18 MN 221 Market Opportunity* Market Acute Asthma COPD Exacerbations US $375 400 million $380 420 million Europe $200 300 million $200 300 million Rest of World $150 250 million $150 250 million Worldwide MN 221 Sales Potential $725 950 million $730 970 million Combined Worldwide MN 221 Sales Potential $1.5 1.9 Billion Source: Physician interviews, team analysis *Prices in today s dollars, do not reflect any price increases which may be implemented *Assumes a conservative price per dose target ~$550/dose MediciNova, Inc. 2012 19 Pharmacoeconomic Benefit: Price of MN 221 vs. % Hospitalizations Source: Guidepoint Global survey of Medical Directors at U.S. managed care companies MediciNova, Inc. 2012 MN 221 Patent Summary The U.S. patent for MN 221 has composition of matter and method of use claims and is set to expire no earlier than February 2017 Corresponding composition of matter patents in various other countries U.S. patent expiration does not include Waxman Hatch patent term restoration (industry average = 4.5 years) Waxman Hatch grants 5 years of exclusivity from approval in the U.S.

Secondary endpoint is to evaluate pharmacokinetics and preliminary efficacy of repeated administration of MN 221 in COPD patients Top line results expected 2Q, 2012 MN 221 CL 012: Ongoing Phase 1b Trial 14 MediciNova, Inc. 2012 MN 221 Clinical Development Acute Asthma Program: Multiple doses tested at infusion length of 15min, 1hr, and 2hr Completed 2 trials in asthmatics with stable disease CL 004 CL 005 Completed Phase 2a trial in patients with AEA in the ED CL 006 Ongoing Phase 2b proof of concept study in patients with AEA in ED CL 007 Phase 3 trials N.

EDs annually 1 st line therapy in ED: Patients receive SOC, many while in the waiting room 2 nd line therapy in ED: Patients who do not initially respond continue receiving SOC Large Market Opportunity for MN 221 1,900,000 1,900,000 Hospitalization: Patients who do not respond to SOC are eventually hospitalized COST ~ $6,477/patient Patients who respond to initial therapy and are discharged Patients who eventually respond to standard therapy and are discharged MediciNova, Inc. 2012 Randomized, placebo controlled, double blind, multi center Phase 2 clinical trial Up to 170 200 patients with severe, acute exacerbations of asthma (FEV 1 50% predicted) at multiple US emergency department sites Two treatment groups of up to 85 100 patients/group 1,200 g infusion of MN 221 over 1hr (600 g in first 15 minutes followed by 600 g in next 45 minutes) + Standard of Care Standard of Care alone + placebo infusion Enrollment almost complete; top line results expected 1Q, 2012 MN 221 CL 007: Ongoing Phase 2b Trial 12 MediciNova, Inc. 2012 MN 221 CL 007 Efficacy Endpoints 13 MN 221 Asthma Clinical Endpoints for CL 007 Phase 2b Trial 1 2 3 FEV 1 Area Under the Curve (AUC) of the change from baseline in FEV 1 (% predicted) during the 3 hour Treatment Period Reduction in Hospital Admissions Clearly recognized Clinical and Pharmacoeconomic Benefit Improvement in Clinical Signs of Asthma Respiratory Rate Accessory Muscle Use Supplemental Oxygen Use MediciNova, Inc. 2012 Randomized, placebo controlled, double blind, Phase 1b clinical trial 20 stable moderate to severe COPD patients (30% FEV 1 80%) Two treatment groups 1,200 g infusions of MN 221 every 12 hours (15 pts.) for 3 days Placebo (5 pts.) Primary objective is to determine the safety and tolerability of MN 221 compared to placebo when administered multiple times over several days in COPD patients who may also have co morbidities and concomitant medications common in this population.

Improved Efficacy Route of administration (IV vs. inhalation) 2. Improved Safety High selectivity for receptor versus Partial agonist for receptor* 3. Reduced Health Care Expenses Reduction in hospitalizations 10 MN 221: A New Approach to Treating Acute Exacerbations (Asthma COPD) receptors are primarily responsible for cardiovascular stimulation MediciNova, Inc. 2012 *Source: Weber, Silverman et al, American Journal of Medicine, 2002, Volume 113; pp 371 11 Acute Asthma Treatment Flow in Emergency Departments (EDs) in the U.S. 965,000 935,000 935,000 410,000 525,000 525,000 Input: 1,900,000 patients with acute exacerbations of asthma present at U.S.

COPD exacerbations are associated with a significant increase in mortality, hospitalization and healthcare utilization. COPD Exacerbations COPD patients are generally more ill than asthmatics with overall higher hospitalizations and mortality. COPD Discharged Hospitalized 72% 28% 1,900 Asthma 52% 48% 1,500 Hospitalization rates amongst Asthma and COPD patients Thousands Source: CDC, CDC COPD surveillance in U.S. 2000; US Census; American Lung Association website For COPD pts. with anemia; for pts. w/o anemia the stay is ~5.8 days at a cost of ~$25K 1.5 million hospital emergency department visits 765,000 hospitalizations Average length of stay 7.4 days Average cost ~$32,000* 119,000 deaths MediciNova, Inc. 2012 MN 221: A novel, highly selective adrenergic receptor agonist Potential advantages over current therapy: 1.

(~560,000 in UK/Spain/Germany/France/Italy) Average length of stay for asthma hospitalization is 3.3 days Average cost for asthma hospitalization is $6,477 Current Standard of Care (SOC): Inhaled beta agonists, inhaled anticholinergics, and IV or oral corticosteroids Current Treatments are limited by Bronchoconstriction (Insufficient air flow due to inflammation and airway constriction prevents inhaled drug uptake in the lungs) and Mucus Plug Formation (Persistent airflow limitation due to mucus secretion *Source: National Center for Health Statistics / CDC, WHO website, Core Health indicators , 2007 National Hospital Discharge Survey, IMS Health s Disease and Condition Benchmarks PharMetrics Integrated Database, 1/2007 12/2008 MediciNova, Inc. 2012 9 A COPD exacerbation is a sustained worsening of the patient's condition, from the stable state and beyond normal day to day variations, that is acute in onset.

Internal development of compound towards commercialization in North America 2. Seek partnership for further development of compound ex U.S. Business Model: Return On Investment MediciNova, Inc. 2012 Product Candidates Preclinical Phase 1 Phase 2 Phase 3 Bedoradrine Sulfate (MN 221) Program Acute Exacerbations of Asthma Exacerbations of COPD Preterm Labor Ibudilast (MN 166/AV11) Program Progressive Multiple Sclerosis Neuropathic Pain Drug Addiction Asthma, IC, Cancer, GAD, OAB, Thrombosis Commercially Attractive Diversified Portfolio 5 Non Core Programs (Various stage of development available for out licensing) MediciNova, Inc. 2012 6 Significant Milestones Anticipated completion dates based on current projections Tentative based on availability of non dilutive financing Milestone: Timeline: Complete an Equity Raise ($~7.9M net) 1Q, 2011 Commence Enrollment in Phase 1 Ibudilast trial for Meth. addiction 2Q, 2011 Sign Chinese Joint Venture for MN 221 2Q, 2011 Commence Enrollment in Phase 2 Ibudilast trial for MOH Pain 3Q, 2011 Complete Equity Raise and Funding from Kissei ($10M) 4Q, 2011 Top line Results from Phase 2b MN 221 CL 007 Acute Asthma Trial 1Q, 2012 Top line Results from Phase 1b Multi Dose Trial in COPD 2Q, 2012 Plan to Initiate Phase 2b Clinical Program for Ibudilast (MS /Pain) 2H, 2012 MN 221: Acute Exacerbations of Asthma Exacerbations of COPD MediciNova, Inc. 2012 8 Acute Exacerbations of Asthma (AEA) Definition: Long lasting and severe asthma episode that is not responsive to initial bronchodilator or corticosteroid therapy Market Opportunity*: Approximately 1.9 million annual emergency room visits in the U.S. ~500,000 annual hospitalizations in U.S.

MediciNova, Inc. 2012 4 In License: Novel, small molecule product candidates with significant clinical or preclinical data packages and attractive market opportunities Conduct Proof of Concept Clinical Trials: Conduct Phase 1 and Phase 2 clinical trials to demonstrate safety and efficacy of compound Two Pathways After Phase 2 (Proof of Concept): 1.

You are cautioned not to place undue reliance on these forward looking statements, which speak only as of February 14, 2012. MediciNova disclaims any intent or obligation to revise or update these forward looking statements. MediciNova, Inc. 2012 MediciNova Overview: Founded in September 2000 Headquartered in San Diego, CA, with an additional office in Tokyo, Japan Dual listing on NasdaqGM as MNOV and Osaka Securities Exchange as 4875 $39.2 million market cap (NasdaqGM) as of 2/14/2012 (aggregate value of 18.3 million shares outstanding of common + preferred on an as converted basis) In Licensed Clinical Stage Compounds: Unique access to differentiated, potentially high value assets primarily from Japanese alliances (Kissei, Kyorin, Mitsubishi Tanabe Pharma, Meiji) New Approaches to Treat Serious Medical Conditions: Bedoradrine Sulfate ( MN 221 ): Intravenous (IV) treatment for exacerbations of asthma and chronic obstructive pulmonary disease (COPD) Ibudilast ( MN 166 /AV411): Oral treatment for progressive multiple sclerosis, neuropathic pain, and drug addiction 3 Corporate Overview: MediciNova, Inc.

These forward looking statements may be preceded by, followed by or otherwise include the words believes, expects, anticipates, intends, estimates, projects, can, could, may, will, would, or similar expressions. Actual results or events may differ materially from those expressed or implied in any forward looking statements due to various factors, including the risks and uncertainties inherent in clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities, the timing of expected filings with the FDA, MediciNova s failure to execute strategic plans or strategies successfully, MediciNova s collaborations with third parties, MediciNova s ability to integrate its two ibudilast development programs and to pursue discussions with potential partners to secure a strategic collaboration to advance the clinical development of the combined development program, the availability of funds to complete product development plans and MediciNova s ability to raise sufficient capital when needed, or at all, MediciNova s ability to comply with the covenants in its financing agreements, intellectual property protection, and the other risks and uncertainties described in MediciNova s filings with the Securities and Exchange Commission, including MediciNova s annual report on Form 10 K for the year ended December 31, 2010 and its subsequent periodic reports on Forms 10 Q and 8 K.

These forward looking statements include statements regarding MediciNova s clinical trials supporting the safety and efficacy of its product candidates and the potential novelty of such product candidates as treatments for disease, plans and objectives for clinical trials and product development, strategies, future performance, expectations, assumptions, financial condition, liquidity and capital resources.

MediciNova, Inc. 2012 Accelerating the global development and commercialization of innovative pharmaceuticals Exhibit 99.1 MediciNova, Inc. 2012 Forward Looking Statements Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investigator Led Development 46 Ibudilast References 47 MediciNova, Inc. 2012